Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Minska andfåddhet med Dronabinol hos KOL-patienter (BONG)

2 oktober 2026 uppdaterad av: Vejle Hospital

BONG: Minska svår andfåddhet med dronabinol i patienter med svår och mycket svår kronisk obstruktiv lungsjukdom - en randomiserad, dubbelblind, placebokontrollerad, crossover-studie

This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).

Studieöversikt

Status

Avslutad

Betingelser

Detaljerad beskrivning

This study is a randomized, controlled, double-blind, crossover trial evaluating the effectiveness of the pharmaceutical drug Dronabinol in patients with severe and very severe COPD.

The researchers will compare the effects of Dronabinol with a placebo (an identical-looking substance that contains no active drug) to determine if Dronabinol reduces breathlessness in COPD patients.

After enrollment, study subjects will undergo four weeks of treatment with both Dronabinol and the placebo in a blinded and randomized sequence. There is a two-week washout period between treatments. During these treatment phases, subjects will complete questionnaires about their daily experiences of breathlessness and wear a watch that records various health parameters.

The study includes eight visits: the initial enrollment and follow-up checks every two weeks. At these visits, subjects undergo tests for lung function and walking distance, and complete health status questionnaires. Additionally, blood samples for THC levels and hair samples for cortisol analysis are collected.

Studietyp

Interventionell

Inskrivning (Faktisk)

30

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Region Syddanmark
      • Vejle, Region Syddanmark, Danmark, 7100
        • Vejle Hospital - A part of Lillebaelt Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Refractory dyspnea despite optimal treatment
  • COPD (GOLD 3,4)
  • Breathlessness corresponding to mMRC score ≥ 3
  • Informed written consent
  • Age ≥ 18 years
  • Cognitive relevant, of legal age
  • Understands and speaks Danish
  • For fertile women defined by amenorrhea for less than 12 months: negative HCG before entry into the trial
  • For fertile and sexually active subjects: use of safe contraception during medication intake and 4 weeks after: intrauterine device (IUD) or hormonal contraception (oral contraceptive pill, implant, transdermal patch, vaginal ring or depot injection).

Exclusion Criteria:

  • Ongoing infection or exacerbation of COPD within the last month (30 days)
  • Regular treatment with THC or CBD within 1 month (30 days)
  • Life expectancy less than 3 months (90 days)
  • Treatment with medicines that, according to the summary of product characteristics, are strong inhibitors or inducers of CYP3A4, CYP2C9 or CYP2C19
  • History of or current evidence of significant medical or psychiatric disorder that is considered by the investigator to put the subject at greater risk of experiencing an adverse event
  • Current or past substance abuse where the investigator finds it too risky for the subject to be included in the study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dronabinol 20 mg, then placebo

In this arm, the study subject will first receive dronabinol 2.5 mg capsules. For two weeks the subject will titrate dose with one capsule corresponding to 2.5 mg dronabinol every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 20 mg daily treatment over a period of 2 weeks. After a wash out period of 2 weeks, study subject will receive placebo capsules (matching dronabinol 2.5 mg capsules). For two weeks the subject will titrate with one capsule every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 8 daily placebo capsules over a period of 2 weeks.

Dronabinol 2.5 mg pr capsule. Titration up till 20 mg daily dose.

Andra namn:
  • Delta9-tetrahydrocannabinol

Dronabinol-matched placebo capsule containing no active substance.

Placebo-jämförare: Placebo, then dronabinol 20 mg

In this arm, the study subject will first receive placebo capsules (matching dronabinol 2.5 mg capsules). For two weeks the subject will titrate with one capsule every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 8 daily placebo capsules over a period of 2 weeks. After a wash out period of 2 weeks, study subject will receive dronabinol 2.5 mg capsules. For two weeks the subject will titrate dose with one capsule corresponding to 2.5 mg dronabinol every other day until 20 mg. Doses are divided into three times a day. After up titration the subject will receive 20 mg daily treatment over a period of 2 weeks.

Dronabinol 2.5 mg pr capsule. Titration up till 20 mg daily dose.

Andra namn:
  • Delta9-tetrahydrocannabinol

Dronabinol-matched placebo capsule containing no active substance.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Difference in Numeric Rating Scale score of discomfort of daily breathlessness between active treatment and placebo
Tidsram: Assessed daily in the baseline period and through both treatment periods. Up to 70 days

Numeric rating scale score range 0-10. Higher score reflects higher discomfort of breathlessness

Assessed daily in the baseline period and through both treatment periods. Up to 70 days
Difference in Numeric Rating Scale score of breathlessness interference of daily activities between active treatment and placebo
Tidsram: Assessed daily in the baseline period and through both treatment periods. Up to 70 days

Numeric rating scale score range 0-10. Higher score reflects more breathlessness interference on daily activities

Assessed daily in the baseline period and through both treatment periods. Up to 70 days
Correlation between breathlessness rated on a daily numeric rating scale in relation to amount of THC blood level of the active treatment period
Tidsram: Assessed daily in the baseline period and through both treatment periods. Up to 70 days

Numeric rating scale score range 0-10. Higher score reflects higher discomfort of breathlessness

Assessed daily in the baseline period and through both treatment periods. Up to 70 days
Correlation between breathlessness interference of daily activities rated on a numeric rating scale in relation to amount of THC blood level of the active treatment period
Tidsram: Assessed daily in the baseline period and through both treatment periods. Up to 70 days

Numeric rating scale score range 0-10. Higher score reflects more breathlessness interference on daily activities

Assessed daily in the baseline period and through both treatment periods. Up to 70 days

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Difference in Multidimensional Dyspnea Profile questionnaire score between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

Assesses different dimensions of COPD.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in COPD Assessment Test questionnaire score between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

Assesses the severity of physical COPD symptoms.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in Chronic Respiratory Disease Questionnaire score between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

A HRQL tool which incorporates patient perceptions of both physical and emotional health.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in Hospital Anxiety and Depression Scale questionnaire score between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

Assess anxiety and depression symptoms in medical patients.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in Medical Research Council Dyspnea Scale questionnaire score between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

A simple and valid method of categorizing patients with COPD in terms of their disability that could be used to complement FEV1 in the classification of COPD severity.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in Epworth Sleepiness Scale questionnaire score between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

Assesses person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in the spirometry parameter forced expiratory volume in 1. second (FEV1) between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

The FEV1 indicates the lung tissue's ability to release air during the first second of exhalation.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in the spirometry parameter forced vital capacity (FVC) between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

The FVC indicates the lung tissue's ability to release air during the entire exhalation.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in the spirometry parameter FEV1/FVC (ratio), between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

Can indicate an obstructive pattern in the exhalation which are used in the diagnosis of COPD.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in six-minute walk test(6MWT) between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

6 minutes walking test measures breathlessness and performance ability.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference Borg dyspnea score conducted in relation to 6MWT between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

A numeric scale from 0 (no breathlessness) to 10 (extremely strong breathlessness) but not limited to 10 if subjects feel breathlessness above 10

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in cortisol level in the hair samples between active treatment and placebo period
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

Measurement of stress through cortisol levels in the hair.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Difference in clinical parameters between active treatment and placebo period using a yet unspecified continuous monitoring device.
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

For several days in each treatment period we continuously measure blood oxygen saturation, electrodermal activity, pulse rate, sleep recording, temperature, respiratory rate, and activity counter.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)
Difference in stand-to-sit-test between active treatment and placebo
Tidsram: Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

A measurement for physical capability until breathlessness.

Baseline (T1; day 1) and after each treatment period (T4; day 28, T7; day 70)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Ole Hilberg, Prof., MD, Medical Department, Vejle Hospital

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

26 februari 2025

Primärt slutförande (Faktisk)

21 september 2026

Avslutad studie (Faktisk)

21 september 2026

Studieregistreringsdatum

Först inskickad

22 maj 2024

Först inskickad som uppfyllde QC-kriterierna

18 juni 2024

Första postat (Faktisk)

25 juni 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

It is the plan to share SAP when this is finalized. It is undecided whether CSR and analytic code will be shared on a platform or available on reasonable request.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera